Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trastuzumab deruxtecan 1trametinib 1toripalimab 1surufatinib 1pembrolizumab 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1cemiplimab 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Glutamine × Tumor-Agnostic × Clear all
NCT07287592 2025-12-17

Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.

Ain Shams University

Phase 3 Not yet recruiting
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡